Cubist gains broader fast-track status for antibiotic

05/8/2013 | Boston Herald

The FDA has widened the fast-track status for Cubist Pharmaceuticals' CXA-201 drug to include hospital-acquired bacterial pneumonia and complicated urinary tract infections. The therapy targets pathogens including multidrug resistant Pseudomonas aeruginosa.

View Full Article in:

Boston Herald

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD